Keros Therapeutics (KROS) Downgraded by Zacks Investment Research to Hold

Keros Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Keros Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Keros Therapeutics traded up $1.74 on Monday, reaching $38.69. 0 shares of the stock traded hands, compared to its average volume of 255771. Shares of Keros Therapeutics were trading at $38.69 on Monday. The firm’s 50 day moving average is $34.35 and its 200 day moving average is $50.99.Keros Therapeutics has a 12 month low of $37.00 and a 12 month high of $88.80. While on yearly highs and lows, Keros Therapeutics’s today has traded high as $38.82 and has touched $37.00 on the downward trend. See More Analyst Rating at: RATING

Keros Therapeutics Earnings and What to expect: 

Keros Therapeutics last announced its quarterly earnings data on August 5th, 2021. The reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by $0.01. The business had revenue of $0.10 million for the quarter. Keros Therapeutics has generated ($2.93) earnings per share over the last year (($2.44) diluted earnings per share). Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.84) per share. Keros Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.84) per share. The P/E ratio of Keros Therapeutics is -15.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Keros Therapeutics is -15.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Keros Therapeutics has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Keros Therapeutics (KROS) Moving Average Technical Analysis

5 day Moving Average is $37.95 And 5 day price change is -$0.65 (-1.65%)  with average volume for 5 day average is 119,640. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $35.67 and 20 day price change is $7.77 (25.13%) and average 20 day moving volume is 314,065. 50 day moving average is $34.35  and 50 day price change is $1.89 ( 5.14%)  and with average volume for 50 days is : 184,912. 200 day moving average is $50.99  and 200 day price change is -$39.06 (-50.24%)  and with average volume for 200 days is : 144,436.

Other owners latest trading in Keros Therapeutics :

  • On 9/17/2021 shares held by Virtu Financial LLC were 5,144 which equates to market value of $0.22M and appx 0.00% owners of Keros Therapeutics
  • On 9/10/2021 shares held by Jasper Ridge Partners L.P. were 45,473 which equates to market value of $1.93M and appx 0.10% owners of Keros Therapeutics
  • On 8/25/2021 shares held by Marshall Wace LLP were 12,055 which equates to market value of $0.51M and appx 0.00% owners of Keros Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 60.48% for Keros Therapeutics

See More Analyst Rating at: RATING